ArticleEuropean journal of cancer (Oxford, England : 1990)2021

Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.

Suzanne George et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.